Inventor
GOTTESMAN OMRI
US18 patents
⚠️ This page may combine multiple inventors who share the name “GOTTESMAN OMRI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
EMPIRICO INC
10 patentsUS11116778B2Sep 14, 2021
Prodrugs of ALOX-15 inhibitors and methods of using the same
EMPIRICO INC9 citations83
US11879125B2Jan 23, 2024
GalNAc compositions for improving siRNA bioavailability
EMPIRICO INC3 citations72
US11377658B2Jul 5, 2022
Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseases
EMPIRICO INC2 citations70
US10941404B2Mar 9, 2021
Treatment of angiopoietin like 7 (ANGPTL7) related diseases
EMPIRICO INC2 citations69
US12258563B2Mar 25, 2025
Modified oligonucleotides
EMPIRICO INC0 citations60
US12258564B2Mar 25, 2025
GalNAc compositions for improving siRNA bioavailability
EMPIRICO INC0 citations60
US11666588B2Jun 6, 2023
Prodrugs of ALOX-15 inhibitors and methods of using the same
EMPIRICO INC0 citations59
US11452738B2Sep 27, 2022
Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
EMPIRICO INC0 citations59
US12378556B2Aug 5, 2025
Treatment of angiopoietin like 7 (ANGPTL7) related diseases
EMPIRICO INC0 citations58
US12312586B2May 27, 2025
Treatment of MST1 related diseases and disorders
EMPIRICO INC0 citations53
REGENERON PHARMA
7 patentsUS10787647B2Sep 29, 2020
HSD17B13 variants and uses thereof
REGENERON PHARMA10 citations81
US11845963B2Dec 19, 2023
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations71
US11753628B2Sep 12, 2023
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations71
US11180757B1Nov 23, 2021
17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
REGENERON PHARMA3 citations71
US11485958B2Nov 1, 2022
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations70
US12359201B2Jul 15, 2025
17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
REGENERON PHARMA0 citations61
US11708415B2Jul 25, 2023
Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1
REGENERON PHARMA1 citations57